|
|
Volumn 8, Issue 10, 2007, Pages 903-906
|
|
Diagnosis or drug? Will pharmaceutical companies or diagnostics manufacturers earn more from personalized medicine?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
TRASTUZUMAB;
ARTICLE;
BREAST CANCER;
BREAST SURGERY;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
COHORT ANALYSIS;
COST CONTROL;
COST OF ILLNESS;
DIAGNOSTIC TEST;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
FLUORESCENCE IN SITU HYBRIDIZATION;
FOOD AND DRUG ADMINISTRATION;
GENETIC SCREENING;
GENOMICS;
HEALTH CARE COST;
HEALTH INSURANCE;
HISTOPATHOLOGY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOASSAY;
IMMUNOHISTOCHEMISTRY;
MEDICAL DECISION MAKING;
MEDICAL SPECIALIST;
MICROFLUIDIC ANALYSIS;
PHARMACOGENETICS;
PREDICTION;
PRESCRIPTION;
PRIORITY JOURNAL;
PROFIT;
PROTEOMICS;
REIMBURSEMENT;
REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;
UNSPECIFIED SIDE EFFECT;
VALIDATION STUDY;
VIRUS DETECTION;
EVIDENCE-BASED MEDICINE;
GENETIC PREDISPOSITION TO DISEASE;
HUMANS;
MOLECULAR DIAGNOSTIC TECHNIQUES;
PHARMACOGENETICS;
|
|
EID: 34848894620
PISSN: 1469221X
EISSN: 14693178
Source Type: Journal
DOI: 10.1038/sj.embor.7401080 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|